检索结果 - Kimberly Stegmaier

Refine Results
  1. 1
    New Approaches to Target T-ALL

    New Approaches to Target T-ALL 由 Giovanni Roti, Kimberly Stegmaier

    出版 2014
    获取全文 获取全文
    Revisão
    加到收藏夹
    Saved in:
  2. 2
    A method for high-throughput gene expression signature analysis.

    A method for high-throughput gene expression signature analysis. 由 D. D. Peck, Emily Crawford, Kenneth N. Ross, Kimberly Stegmaier, Todd R. Golub, Justin Lamb

    出版 2006
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  3. 3
    Gefitinib induces myeloid differentiation of acute myeloid leukemia

    Gefitinib induces myeloid differentiation of acute myeloid leukemia 由 Kimberly Stegmaier, Steven M. Corsello, Kenneth N. Ross, Jenny Wong, Daniel J. DeAngelo, Todd R. Golub

    出版 2005
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  4. 4
    Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation

    Gene expression–based high-throughput screening(GE-HTS) and application to leukemia differentiation 由 Kimberly Stegmaier, Kenneth N. Ross, Sierra A. Colavito, Shawn M. O'Malley, Brent R. Stockwell, Todd R. Golub

    出版 2004
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  5. 5
    SYK regulates mTOR signaling in AML

    SYK regulates mTOR signaling in AML 由 Julia Carnevale, Linda Ross, Alexandre Puissant, Versha Banerji, Richard M. Stone, Daniel J. DeAngelo, Kenneth N. Ross, Kimberly Stegmaier

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  6. 6
    <i>RAD21</i> is a driver of chromosome 8 gain in Ewing sarcoma to mitigate replication stress

    <i>RAD21</i> is a driver of chromosome 8 gain in Ewing sarcoma to mitigate replication stress 由 Xiaofeng A. Su, Duanduan Ma, James V. Parsons, John Replogle, James F. Amatruda, Charles A. Whittaker, Kimberly Stegmaier, Angelika Amon

    出版 2021
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  7. 7
    Phase II study of intermediate‐dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group

    Phase II study of intermediate‐dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group 由 Steven G. DuBois, Mark Krailo, Stephen L. Lessnick, Richard A. Smith, Zhengjia Chen, Neyssa Marina, Holcombe E. Grier, Kimberly Stegmaier

    出版 2008
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  8. 8
    Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia

    Mitochondrial fusion is a therapeutic vulnerability of acute myeloid leukemia 由 Clément Larrue, Sarah Mouche, Shan Lin, Federico Simonetta, Nastassja K. Scheidegger, Laury Poulain, Rudy Birsen, Jean‐Emmanuel Sarry, Kimberly Stegmaier, Jérôme Tamburini

    出版 2023
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  9. 9
    Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood

    Frequent loss of heterozygosity at the TEL gene locus in acute lymphoblastic leukemia of childhood 由 Kimberly Stegmaier, Shona Pendse, G. F. Barker, Patricia Bray‐Ward, DC Ward, KT Montgomery, KS Krauter, Charles H. Reynolds, Jeffrey Sklar, M Donnelly

    出版 1995
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  10. 10
    Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing Sarcoma

    Signature-Based Small Molecule Screening Identifies Cytosine Arabinoside as an EWS/FLI Modulator in Ewing Sarcoma 由 Kimberly Stegmaier, Jenny Wong, Kenneth N. Ross, Kwan T. Chow, D. D. Peck, Renee D. Wright, Stephen L. Lessnick, Andrew L. Kung, Todd R. Golub

    出版 2007
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  11. 11
    Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation

    Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation 由 Cynthia K. Hahn, Kenneth N. Ross, Ian M. Warrington, Ralph Mazitschek, Cindy M. Kanegai, Renee D. Wright, Andrew L. Kung, Todd R. Golub, Kimberly Stegmaier

    出版 2008
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  12. 12
    Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma

    Functional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma 由 Alyssa L. Kennedy, Mounica Vallurupalli, Liying Chen, Brian D. Crompton, Glenn S. Cowley, Francisca Vázquez, Barbara A. Weir, Aviad Tsherniak, Sudha Parasuraman, Sunkyu Kim, Gabriela Alexe, Kimberly Stegmaier

    出版 2015
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  13. 13
    TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia

    TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia 由 TW McLean, Sarah Ringold, Donna Neuberg, Kimberly Stegmaier, Ramana Tantravahi, Jerome Ritz, HP Koeffler, Seisho Takeuchi, JW Janssen, Taku Seriu, CR Bartram, SE Sallan, DG Gilliland, TR Golub

    出版 1996
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  14. 14
    Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo

    Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression in vivo 由 Yusuke Tarumoto, Shan Lin, Jinhua Wang, Joseph P. Milazzo, Yali Xu, Bin Lü, Zhaolin Yang, Yiliang Wei, Sofya A. Polyanskaya, Mark Wunderlich, Nathanael S. Gray, Kimberly Stegmaier, Christopher R. Vakoc

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  15. 15
    TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia

    TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia 由 TW McLean, Sarah Ringold, Donna Neuberg, Kimberly Stegmaier, Ramana Tantravahi, Jerome Ritz, HP Koeffler, Seisho Takeuchi, JW Janssen, Taku Seriu, CR Bartram, SE Sallan, DG Gilliland, TR Golub

    出版 1996
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  16. 16
    Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer

    Complementary Genomic Screens Identify SERCA as a Therapeutic Target in NOTCH1 Mutated Cancer 由 Giovanni Roti, Anne L. Carlton, Kenneth N. Ross, Michele Markstein, Kostandin V. Pajcini, Angela Su, Norbert Perrimon, Warren S. Pear, Andrew L. Kung, Stephen C. Blacklow, Jon C. Aster, Kimberly Stegmaier

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  17. 17
    High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma

    High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma 由 Brian D. Crompton, Anne L. Carlton, Aaron R. Thorner, Amanda L. Christie, Jinyan Du, Monica L. Calicchio, Miguel N. Rivera, Mark D. Fleming, Nancy E. Kohl, Andrew L. Kung, Kimberly Stegmaier

    出版 2013
    获取全文
    Artigo
    加到收藏夹
    Saved in:
  18. 18
    Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2

    Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2 由 Jonathan R. LaRochelle, Michelle Fodor, Jana M. Ellegast, Xiaoxi Liu, Vidyasiri Vemulapalli, Morvarid Mohseni, Travis Stams, Sara J. Buhrlage, Kimberly Stegmaier, Matthew J. LaMarche, Michael Acker, Stephen C. Blacklow

    出版 2017
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  19. 19
    EWS–FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex

    EWS–FLI1 modulated alternative splicing of ARID1A reveals novel oncogenic function through the BAF complex 由 Saravana P. Selvanathan, Garrett T. Graham, Alexander Grego, Tabari Baker, J. Robert Hogg, Mark Simpson, Mona Batish, Brian D. Crompton, Kimberly Stegmaier, Eleni M. Tomazou, Heinrich Kovar, Aykut Üren, Jeffrey A. Toretsky

    出版 2019
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:
  20. 20
    Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in <i>ALK</i>-mutated neuroblastoma

    Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in <i>ALK</i>-mutated neuroblastoma 由 Nathan F. Moore, Anna M. Azarova, Namrata Bhatnagar, Kenneth N. Ross, Lauren E. Drake, Stacey M. Frumm, Qinsong S. Liu, Amanda L. Christie, Takaomi Sanda, Louis Chesler, Andrew L. Kung, Nathanael S. Gray, Kimberly Stegmaier, Rani E. George

    出版 2014
    获取全文 获取全文
    Artigo
    加到收藏夹
    Saved in:

检索工具: